Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
NCT07520565 BXOS-110 Androgen-Insensitivity Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07520565 BXOS-110 Androgen-Insensitivity Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07520565 clinical trial report covering BXOS-110, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07520162 Tezepelumab Nail-Patella Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07520162 Tezepelumab Nail-Patella Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07520162 clinical trial report covering Tezepelumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07519902 Cenegermin-BKBJ Persistent corneal epithelial defect Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07519902 Cenegermin-BKBJ Persistent corneal epithelial defect Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07519902 clinical trial report covering Cenegermin-BKBJ, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20261349 Ketoprofen Tenosynovitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20261349 Ketoprofen Tenosynovitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
CTR20261349 clinical trial report covering Ketoprofen, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20261234 RY_SW01 Scleroderma, Systemic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20261234 RY_SW01 Scleroderma, Systemic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
CTR20261234 clinical trial report covering RY_SW01, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07524738 Buprenorphine Hydrochloride Opioid abuse Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07524738 Buprenorphine Hydrochloride Opioid abuse Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07524738 clinical trial report covering Buprenorphine Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20261330 UREA, C-14 Helicobacter pylori infection Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20261330 UREA, C-14 Helicobacter pylori infection Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
CTR20261330 clinical trial report covering UREA, C-14, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
ChiCTR2600122401 Claseprubart Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
ChiCTR2600122401 Claseprubart Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
ChiCTR2600122401 clinical trial report covering Claseprubart, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07522073 INCB-161734 Metastatic Pancreatic Ductal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07522073 INCB-161734 Metastatic Pancreatic Ductal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07522073 clinical trial report covering INCB-161734, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07524413 Pucotenlimab Advanced Nasopharyngeal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07524413 Pucotenlimab Advanced Nasopharyngeal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07524413 clinical trial report covering Pucotenlimab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07524452 Cisplatin Locally Advanced Head and Neck Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07524452 Cisplatin Locally Advanced Head and Neck Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07524452 clinical trial report covering Cisplatin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07522255 Rifaximin Constipation - functional Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07522255 Rifaximin Constipation - functional Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07522255 clinical trial report covering Rifaximin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →